Ovarian Cancer  >>  IMF-001  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMF-001 / ImmunoFrontier
NCT00291473: Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

Completed
1
9
Japan
CHP-HER2, CHP-NY-ESO-1
Ludwig Institute for Cancer Research, Mie University
Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer, Ovarian Cancer
08/08
08/08
NCT01234012: Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Completed
1
23
US
IMF-001
ImmunoFrontier, Inc.
Solid Tumor
11/13
03/14

Download Options